Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Adaptimmune Therapeutics  / Equity Bottom-Up

<ul><li>Key 2Q24 takeaways include: 1) recent FDA approval of Tecelra (afami-cel) triggers immediate onboarding of Authorized Treatment Centers (ATCs), with related sales revenue to start in 4Q24 and accelerate in 2025 and beyond 2) ADAP maintains a diversified pipeline of late-stage programs beyond Tecelra, as well as a deep preclinical pipeline across multiple autologous and allogeneic cell therapies and 3) we expect current liquidity, Tecelra revenue, and funds related to recent loan/collaboration agreements to fund operations through the launch of lete-cel in 2026, thereby removing a lingering concern for some investors.</li><li> The recent FDA approval of Tecelra translates into a real-time step up in related sales/economics, and paves the way for further commercialization opportunities.</li><li>We believe the stock's current price provides investors with an attractive entry point, particularly given the company's enhanced long-term earnings power.</li></ul>

Key 2Q24 takeaways include: 1) recent FDA approval of Tecelra (afami-cel) triggers immediate onboarding of Authorized Treatment Centers (ATCs), with related sales revenue to start in 4Q24 and accelerate in 2025 and beyond 2) ADAP maintains a diversified pipeline of late-stage programs beyond Tecelra, as well as a deep preclinical pipeline across multiple autologous and allogeneic cell therapies and 3) we expect current liquidity, Tecelra revenue, and funds related to recent loan/collaboration agreements to fund operations through the launch of lete-cel in 2026, thereby removing a lingering concern for some investors. The recent FDA approval of Tecelra translates into a real-time step up in related sales/economics, and paves the way for further commercialization opportunities.We believe the stock's current price provides investors with an attractive entry point, particularly given the company's enhanced long-term earnings power.

ADAP 2Q24 Earnings: Tecelra FDA Approval + Capital Reload